ArticleExperimental and therapeutic medicine2015
Anti-candidal activity of a novel peptide derived from human chromogranin A and its mechanism of action against
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections.Frontiers in immunology · 2025Review
- Antimicrobial Peptides with Anti-International journal of molecular sciences · 2022Review
- Antifungal Activity of the Frog Skin Peptide Temporin G and Its Effect onInternational journal of molecular sciences · 2022Article
- Expression of chromogranin A-derived antifungal peptide CGA-N12 inBioengineered · 2020Article
- CGA-N9, an antimicrobial peptide derived from chromogranin A: direct cell penetration of and endocytosis byThe Biochemical journal · 2019Article
- CGA-N12, a peptide derived from chromogranin A, promotes apoptosis ofThe Biochemical journal · 2018Article
- An insight into new strategies to combat antifungal drug resistance.Drug design, development and therapy · 2018Review
- Protective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.